Literature DB >> 12936968

Real-time monitoring of bacterial infection in vivo: development of bioluminescent staphylococcal foreign-body and deep-thigh-wound mouse infection models.

Nelly A Kuklin1, Gregory D Pancari, Timothy W Tobery, Leslie Cope, Jesse Jackson, Charles Gill, Karen Overbye, Kevin P Francis, Jun Yu, Donna Montgomery, Annaliesa S Anderson, William McClements, Kathrin U Jansen.   

Abstract

Staphylococcal infections associated with catheter and prosthetic implants are difficult to eradicate and often lead to chronic infections. Development of novel antibacterial therapies requires simple, reliable, and relevant models for infection. Using bioluminescent Staphylococcus aureus, we have adapted the existing foreign-body and deep-wound mouse models of staphylococcal infection to allow real-time monitoring of the bacterial colonization of catheters or tissues. This approach also enables kinetic measurements of bacterial growth and clearance in each infected animal. Persistence of infection was observed throughout the course of the study until termination of the experiment at day 16 in a deep-wound model and day 21 in the foreign-body model, providing sufficient time to test the effects of antibacterial compounds. The usefulness of both animal models was assessed by using linezolid as a test compound and comparing bioluminescent measurements to bacterial counts. In the foreign-body model, a three-dose antibiotic regimen (2, 5, and 24 h after infection) resulted in a decrease in both luminescence and bacterial counts recovered from the implant compared to those of the mock-treated infected mice. In addition, linezolid treatment prevented the formation of subcutaneous abscesses, although it did not completely resolve the infection. In the thigh model, the same treatment regimen resulted in complete resolution of the luminescent signal, which correlated with clearance of the bacteria from the thighs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12936968      PMCID: PMC182637          DOI: 10.1128/AAC.47.9.2740-2748.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Validation of a noninvasive, real-time imaging technology using bioluminescent Escherichia coli in the neutropenic mouse thigh model of infection.

Authors:  H L Rocchetta; C J Boylan; J W Foley; P W Iversen; D L LeTourneau; C L McMillian; P R Contag; D E Jenkins; T R Parr
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Revealing the spatiotemporal patterns of bacterial infectious diseases using bioluminescent pathogens and whole body imaging.

Authors:  S M Burns; D Joh; K P Francis; L D Shortliffe; C A Gruber; P R Contag; C H Contag
Journal:  Contrib Microbiol       Date:  2001

Review 3.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

4.  Effects of 2 different anti-tumor necrosis factor-alpha agents in a primate model of subcutaneous abscess formation.

Authors:  Xiao-yu R Song; Floyd Fox; Mary Ann Gallo; Amy Rosenberg; Robert Jordan; David Shealy; Carrie Wagner
Journal:  J Infect Dis       Date:  2002-01-03       Impact factor: 5.226

5.  Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposon.

Authors:  K P Francis; J Yu; C Bellinger-Kawahara; D Joh; M J Hawkinson; G Xiao; T F Purchio; M G Caparon; M Lipsitch; P R Contag
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

6.  Monitoring bioluminescent Staphylococcus aureus infections in living mice using a novel luxABCDE construct.

Authors:  K P Francis; D Joh; C Bellinger-Kawahara; M J Hawkinson; T F Purchio; P R Contag
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

7.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.

Authors:  Tamara R Anderegg; Douglas J Biedenbach; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 9.  The changing epidemiology of Staphylococcus aureus?

Authors:  H F Chambers
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

Review 10.  The impact of hospital-acquired bloodstream infections.

Authors:  R P Wenzel; M B Edmond
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

View more
  40 in total

1.  Optical Imaging of Bacterial Infection Models.

Authors:  W Matthew Leevy; Nathan Serazin; Bradley D Smith
Journal:  Drug Discov Today Dis Models       Date:  2007

Review 2.  Noninvasive biophotonic imaging for studies of infectious disease.

Authors:  Nuria Andreu; Andrea Zelmer; Siouxsie Wiles
Journal:  FEMS Microbiol Rev       Date:  2010-10-19       Impact factor: 16.408

Review 3.  Infections associated with medical devices: pathogenesis, management and prophylaxis.

Authors:  Christof von Eiff; Bernd Jansen; Wolfgang Kohnen; Karsten Becker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model.

Authors:  Yan Q Xiong; Julie Willard; Jagath L Kadurugamuwa; Jun Yu; Kevin P Francis; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  Use of a bioluminescent Pseudomonas aeruginosa strain within an in vitro microbiological system, as a model of wound infection, to assess the antimicrobial efficacy of wound dressings by monitoring light production.

Authors:  R M S Thorn; S M Nelson; J Greenman
Journal:  Antimicrob Agents Chemother       Date:  2007-07-16       Impact factor: 5.191

Review 6.  Infected animal models for tissue engineering.

Authors:  Alexander M Tatara; Sarita R Shah; Carissa E Livingston; Antonios G Mikos
Journal:  Methods       Date:  2015-04-02       Impact factor: 3.608

7.  Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin.

Authors:  Avanish K Varshney; Xiaobo Wang; Jennifer MacIntyre; Richard S Zollner; Kerry Kelleher; Oleg V Kovalenko; Ximo Pechuan; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2014-05-05       Impact factor: 5.226

8.  Detection and measurement of staphylococcal enterotoxin-like K (SEl-K) secretion by Staphylococcus aureus clinical isolates.

Authors:  Jorge L Aguilar; Avanish K Varshney; Xiaobo Wang; Lindsay Stanford; Matthew Scharff; Bettina C Fries
Journal:  J Clin Microbiol       Date:  2014-05-07       Impact factor: 5.948

9.  In vivo imaging of bioluminescent Escherichia coli in a cutaneous wound infection model for evaluation of an antibiotic therapy.

Authors:  Samir Jawhara; Serge Mordon
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Construction and application of a luxABCDE reporter system for real-time monitoring of Enterococcus faecalis gene expression and growth.

Authors:  Sabina Leanti La Rosa; Dzung B Diep; Ingolf F Nes; Dag Anders Brede
Journal:  Appl Environ Microbiol       Date:  2012-07-27       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.